(CGON) CG Oncology, Inc. Business Model Canvas Research

Regulatory consultants and medical advisors help CG Oncology, Inc. shape FDA plans for bladder cancer programs, from endpoint design to safety packages and submission strategy. That matters in a high-unmet-need market: the U.S. is expected to see about 83,190 new bladder cancer cases and 16,840 deaths in 2025, so clean, fast regulatory execution can shape value.

• Define FDA-ready endpoints
• Build safety and efficacy packages
• Set submission strategy
• Support unmet-need positioning

Patient advocacy groups help CG Oncology reach bladder cancer patients, explain trials, and build trust in a hard-to-enroll market; the disease caused about 614,000 new cases worldwide in 2022, so even small gains in awareness matter.

• Expand patient reach
• Improve trial education
• Boost disease credibility

CG Oncology, Inc. runs CMC and manufacturing scale-up for its only clinical-stage asset, cretostimogene grenadenorepvec, to support clinical supply now and future commercial launch. Process development and GMP production must keep lot-to-lot consistency and product quality tight as the program moves deeper into late-stage development.

• GMP batches support trials and launch
• Quality control protects lot consistency
• Scale-up matters more in late stage

CG Oncology, Inc. uses medical affairs and scientific communication to share clinical data with investigators, clinicians, and other stakeholders, helping build awareness of its bladder cancer approach and support future adoption.

• Shares trial data with key stakeholders
• Boosts investigator engagement
• Drives treatment awareness and adoption

CG Oncology, Inc. depends on a specialized team of oncology, regulatory, and development staff to run its clinical and manufacturing work. In FY2025, that expertise matters even more because the company is still advancing a focused pipeline, so decisions on trial design, CMC (chemistry, manufacturing, and controls), and FDA interactions must be precise.

• Guides complex trial execution
• Supports manufacturing decisions
• Drives regulatory filings and planning

CG Oncology’s key resource is capital and market access: the Company ended fiscal 2024 with about $839 million in cash, cash equivalents, and marketable securities, while still having no product revenue. That cash funds trials, manufacturing, and operating losses until approval, so access to capital is a core strategic asset.

• About $839 million cash and investments
• No product revenue before approval
• Funds trials, manufacturing, operations

CG Oncology, Inc. targets a durable response, not just short-term control: non-muscle-invasive bladder cancer can recur in up to 70% of patients within 5 years, so complete response plus lasting benefit is the real test. That makes durability a clear edge versus options that fade fast.

• Focus on complete response
• Durability matters in recurrent disease
• Less short-lived than symptom control

CG Oncology, Inc. targets a major uro-oncology gap: about 75% of bladder cancers are non-muscle invasive, and many high-risk patients still face repeat procedures or radical cystectomy. A bladder-sparing option can delay or avoid surgery, which may lower morbidity, preserve quality of life, and cut costs for physicians and payers.

• Bladder-sparing therapy may delay cystectomy
• Matches a large NMIBC treatment gap
• Can reduce patient and payer burden

Patients with bladder cancer need plain education on treatment choices and trial steps, because the disease is common: the American Cancer Society estimated 84,870 new U.S. cases and 17,420 deaths in 2025. For CG Oncology, Inc., patient-centered engagement should stress bladder preservation, simple trial logistics, and trust in high-stakes decisions.

• Clear, plain treatment education
• Lead with bladder preservation
• Explain trial timing and visits
• Build trust for oncology choices

Scientific meetings are a key customer touchpoint for CG Oncology, Inc., where clinicians and researchers review trial data, ask questions, and compare real-world use. This matters in bladder cancer, where peer discussion can shape awareness before and after approval and support uptake of its lead program, cretostimogene grenadenorepvec.

• Shares data with key opinion leaders
• Collects direct clinical feedback
• Builds pre- and post-approval awareness

Specialist physician networks are the main patient-funnel for CG Oncology, Inc.: urologists, uro-oncologists, and bladder cancer referral centers identify the BCG-unresponsive NMIBC pool inside a niche market where U.S. bladder cancer still drives about 83,000 new cases and 16,800 deaths a year. One referral can decide access, so these networks matter more than broad primary-care reach.

• Urologists drive first diagnosis
• Uro-oncologists confirm treatment fit
• Referrals find BCG-unresponsive patients

CG Oncology, Inc. will need FDA approval first, then payer coverage and coding before routine use; the FDA’s standard review goal is 10 months, and a priority review can be 6 months. For a urology therapy, reimbursement from Medicare and commercial plans will decide whether clinicians can actually adopt it at scale.

• FDA approval gates launch.
• Payer coverage drives routine use.
• Reimbursement shapes commercialization speed.

Uro-oncologists and cancer centers are key for CG Oncology, Inc. because they treat the most complex bladder-cancer cases and drive trial referrals. With about 83,000 U.S. bladder-cancer diagnoses a year, these sites help shape early uptake of new therapies and are critical for both development and launch.

• Handle complex, high-acuity cases
• Refer patients into trials
• Drive early therapy adoption
• Support development and launch

U.S. non-muscle invasive bladder cancer recurs in up to 70% of cases, so payers will judge CG Oncology, Inc. on clinical value, recurrence cuts, and fewer cystectomies. Health systems matter if the therapy becomes standard care, because about 83,000 new U.S. bladder cancer cases a year can shift OR use and institutional budgets.

• Coverage must prove recurrence reduction.
• Institutional buying will shape access.
• Surgery avoidance supports payer value.

CG Oncology, Inc. carries a fixed-cost base built around scientific staff, clinical operations, regulatory, finance, and G&A, because a development-stage biotech needs specialized talent before cash comes from sales. As programs move closer to approval and launch, overhead usually rises fast as teams, systems, and compliance work scale up.

• Heavy fixed labor costs
• Clinical and regulatory spend
• G&A rises near launch

CG Oncology, Inc. must fund patent filing, maintenance, and defense work to protect its single lead asset, cretostimogene grenadenorepvec, and that makes legal spend a core cost item. Licensing talks, contract drafting, and litigation risk management also add recurring overhead, especially when one asset carries most of the value.

• Patent and defense costs are non-discretionary.

• Licensing and contracts add legal expense.

• Single-asset risk raises IP spend priority.

CG Oncology, Inc. can earn milestone payments only if partner deals hit set steps, like Phase 3 results, FDA review, or first commercial sales. In 2024, CG Oncology, Inc. still had no product revenue, so these contingent cash inflows can help fund R&D without immediate dilution.

• Cash comes only after progress
• Supports ongoing R&D spending
• Can include regulatory and sales triggers

CG Oncology, Inc. uses government or research support as a small non-dilutive funding stream, so it can soften FY2025 cash burn without changing ownership. In practice, this income is usually minor versus development spend, but it still helps extend the cash runway while the Company funds late-stage bladder-cancer work.

• Non-dilutive, so no equity dilution
• Usually small versus R&D spend
• Can lengthen cash runway